Canaan Partners Biopharmaceuticals Focus

Focus

Technology

Healthcare

»Biopharmaceuticals
»Medical Devices
»Diagnostics

Global

BiPar Sciences, Inc.

BiPar Sciences is a biopharmaceutical organization pioneering novel tumor-selective therapies being investigated in settings of urgent unmet need for cancer patients. Their current focus is in DNA repair, specifically with Poly ADP-Ribose Polymerase (PARP) inhibitors. The research leading to their PARP inhibition platform originated at the University of California, San Francisco (UCSF).

www.biparsciences.com

Chimerix

Chimerix discovers, develops and commercializes therapeutics with enhanced pharmaceutical properties that are active against a broad range of viral diseases. Leveraging a powerful lipid prodrug technology, ProLipTagTM, Chimerix is able to develop drug candidates with oral-availability, increased potency and targeted delivery. Known drugs can be modified to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse reactions. Chimerix is applying its technology towards the discovery and development of oral drugs for the treatment of smallpox, cytomegalovirus infection, drug-resistant HIV infection and viral hepatitis.

www.chimerix-inc.com

Marinus Pharmaceuticals

Marinus is a new specialty pharmaceutical company dedicated to the development and commercialization of novel drugs to treat serious neurological, psychiatric, and pain disorders.
Marinus is progressing two exciting development stage pharmaceutical programs: Ganaxolone is being developed by Marinus for the treatment of epilepsy both in adults and children. Chelerythrine is in pre-clinical development for both the treatment of bipolar disorder and the cognitive deficits of schizophrenia.

www.marinuspharma.com

VaxInnate

VaxInnate is a privately-held biotechnology company developing novel, proprietary vaccines for both pandemic and seasonal influenza. The company’s breakthrough vaccines are based on its Toll-like receptor (TLR) technology platform, which dramatically improves vaccine immunogenicity and efficacy, avoiding many of the challenges and pitfalls of egg-based or cell-culture influenza vaccine production. VaxInnate’s technology has the potential to significantly improve the cost-effectiveness, manufacturing capacity, and potency of influenza vaccines – key issues facing the clinical and public health communities.

www.vaxinnate.com

See all Biopharmaceuticals Companies